Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

RecruitingRare disease

Long-term safety study of Temferon (modified stem cells with interferon-α2) in patients previously treated for glioblastoma multiforme

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study focuses on patients with Glioblastoma Multiforme, an aggressive type of brain cancer. The study evaluates the long-term safety of a treatment called Temferon, which was previously given to patients. Temferon is a special type of therapy that uses the patient's own blood stem cells that have been modified to carry a specific gene.

The treatment involves hematopoietic stem cells (blood-forming cells) that are collected from the patient's own body. These cells are modified in a laboratory to include a gene that produces interferon alpha-2, a substance that can help fight cancer. The modified cells are then given back to the patient through an intravenous infusion (through a vein).

The main purpose of this follow-up study is to monitor the long-term safety of Temferon treatment. The study will specifically look at whether the modified cells could potentially cause any blood disorders or other health issues over time. Patients who have previously received Temferon treatment will be monitored for several years to ensure their safety and to track how well the treatment continues to work.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial participation

    You have previously received Temferon treatment and completed the initial TEM-GBM_001 study.

    You will be monitored for long-term effects of the treatment through regular check-ups.

  2. Step 2

    Medical monitoring

    Your blood will be regularly tested to check for any changes in white blood cells.

    Regular clinical examinations and laboratory tests will be conducted to monitor your health.

    Your brain condition will be evaluated using standard medical imaging to track any changes.

  3. Step 3

    Safety assessments

    Doctors will monitor for any signs of blood disorders or changes in your immune system.

    Your neurological health will be regularly assessed for any new symptoms not related to your original condition.

    Any infections or unexpected health changes will be documented and evaluated.

  4. Step 4

    Treatment response evaluation

    Your response to the previous Temferon treatment will be evaluated using standard medical criteria.

    The medical team will assess if your condition is stable, improving, or changing.

    Your overall health and survival will be monitored from the day you received Temferon.

  5. Step 5

    Long-term follow-up

    The monitoring period will continue until April 30, 2027.

    Regular appointments will be scheduled to track your progress and health status.

    All findings will be documented to understand the long-term effects of the treatment.

Who can join the trial?

7 criteria

  • Must be 18 years or older
  • Must have previously participated in the TEM-GBM_001 study and completed all follow-up visits
  • Must have previously received Temferon treatment (a type of medical therapy)
  • Must be able and willing to provide written informed consent (formal agreement to participate)
  • Must be willing to follow all study procedures and requirements
  • Can be either male or female
  • Must have been diagnosed with glioblastoma multiforme (a type of brain tumor)

Who cannot join the trial?

15 criteria

  • Age under 18 or over 65 years old
  • Pregnant or breastfeeding women
  • History of other cancers in the past 5 years (except successfully treated non-melanoma skin cancer or cervical cancer in situ)
  • Active or chronic infections, including HIV, Hepatitis B, or Hepatitis C
  • Severe kidney problems (creatinine clearance less than 60 mL/min)
  • Severe liver problems (liver enzymes more than 3 times the normal upper limit)
  • Heart conditions including heart failure, recent heart attack, or irregular heartbeat
  • Uncontrolled high blood pressure (blood pressure higher than 150/90 mmHg)
  • History of autoimmune diseases (conditions where the immune system attacks healthy cells)
  • Mental health conditions that could affect ability to provide informed consent
  • Current participation in other clinical trials
  • Known allergies to any components of the study treatment
  • Life expectancy less than 3 months
  • Unable to undergo MRI scans (such as having metal implants or claustrophobia)
  • History of substance abuse in the past 2 years
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Temferon

    is a specialized cell therapy that uses the patient's own blood stem cells (CD34+ cells). These cells are modified in a laboratory using a special virus carrier (lentiviral vector) to make them produce interferon-α2, a protein that helps fight cancer. The modified cells are then given back to the patient to help treat glioblastoma multiforme, a type of brain cancer. This therapy aims to deliver targeted treatment directly to the tumor area.

  • Interferon-α2

    is a natural protein that the body produces to fight diseases. In this treatment, it is produced by the modified cells to help combat the brain tumor. It works by boosting the immune system and potentially slowing down tumor growth.

What is already known about the treatment

Temferon – A genetically modified cell therapy that uses the patient's own (autologous) CD34+ hematopoietic progenitor cells, which are modified using a lentiviral vector to express interferon-α2, specifically designed for the treatment of glioblastoma multiforme (GBM). This advanced therapy is administered through cell infusion and represents a novel approach in treating aggressive brain tumors by combining cell therapy with gene modification. The treatment works by using modified blood stem cells to deliver interferon-α2 to the tumor site, potentially enhancing the body's immune response against the cancer cells while being studied for long-term safety and effectiveness in clinical trials.

Investigated diseases

Glioblastoma multiforme (GBM) - A type of brain cancer that forms from glial cells, which normally support and protect nerve cells in the brain. It is characterized by the rapid growth of abnormal cells that form tumors in the brain tissue. The disease affects the cerebral hemispheres of the brain, though it can develop in other parts of the brain as well. GBM can cause various symptoms depending on its location, including headaches, seizures, changes in behavior, and problems with memory or speech. The tumor typically grows and spreads quickly within brain tissue, creating pressure within the skull.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase ITrial ID2024-516211-25-00Protocol codeTEM-LTEstimated enrolment5 patientsSponsorGenenta Science S.p.A.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.